Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Loreto Sulit

Critical Care Medicine Chandler, AZ Medical Doctor

NPI 1902890767 CMS profile 132045

1955 W Frye Rd, Chandler, AZ 85224

Open in the dashboard

General payments

$6,085

289 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Loreto Sulit of Chandler, AZ is reported in the CMS Open Payments database as having received $6,085 across 289 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $850 41
2024 General $832 38
2023 General $1,101 50
2022 General $1,244 46
2021 General $765 35
2020 General $303 19
2019 General $991 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Loreto Sulit
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Loreto Sulit were reported at $850. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Loreto Sulit Critical Care Medicine median Middle half National median
2019 $991 $149 $51–$535 $163
2020 $303 $110 $30–$325 $114
2021 $765 $125 $34–$403 $132
2022 $1,244 $157 $49–$582 $149
2023 $1,101 $162 $56–$621 $160
2024 $832 $168 $53–$634 $164
2025 $850 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $785 41 payments
  2. GlaxoSmithKline, LLC. $781 47 payments
  3. Insmed, Inc. $465 17 payments
  4. Jazz Pharmaceuticals Inc. $423 12 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $379 17 payments
  6. Harmony Biosciences LLC $294 14 payments
  7. Abiomed $247 2 payments
  8. Mylan Specialty L.P. $237 13 payments
  9. Actelion Pharmaceuticals US, Inc. $231 10 payments
  10. Baxter Healthcare $202 12 payments
  11. Other $2,042 104 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,848 286 payments
  2. Education $237 3 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $534 34 payments
  2. Arikayce $465 17 payments
  3. BREZTRI $398 13 payments
  4. FASENRA $287 5 payments
  5. SPIRIVA RESPIMAT $257 14 payments
  6. Impella $247 2 payments
  7. TEZSPIRE $230 4 payments
  8. NUCALA $230 12 payments
  9. XYWAV $204 7 payments
  10. YUPELRI $194 10 payments
  11. Other $4,109 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

872

Median for Pulmonary Disease: 936

Drug cost

$245,405

Median for Pulmonary Disease: $487,987

Branded share of claims

54.7%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 95 $92,411
Dupixent Syringe Dupilumab Brand 13 $57,382
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 19 $16,625
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 24 $16,374
Symbicort Budesonide/Formoterol Fumarate Brand 30 $8,763
Spiriva Respimat Tiotropium Bromide Brand 16 $8,186
Eliquis Apixaban Brand 12 $7,552
Breo Ellipta Fluticasone/Vilanterol Brand 11 $5,083
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 32 $4,981
Incruse Ellipta Umeclidinium Bromide Brand 13 $4,475

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$139,584

Medicare's payments for the services billed

Medicare patients

569

Average age 75

Services billed

1,394

274 women, 295 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 54%
Diabetes 42%
Chronic kidney disease 42%
Atrial fibrillation 41%
COPD 41%
Heart failure 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $89
$89 95 —
Arikayce
  • Insmed, Inc. $85
$85 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $83
$83 13 —
WAKIX
  • Harmony Biosciences LLC $67
$67 — —
YUPELRI
  • Mylan Specialty L.P. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

289 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record